GLP-1 receptor agonists for obesity: eligibility across 99 countries.

Yoo SGK, Teufel F, Theilmann M, Si Y, Toure EA, Aryal K, Bärnighausen T, Bait A, Barreto M, Bovet P, Brant LCC, Cuschieri S, Damasceno A, Farzadfar F, Fawwad A, Geldsetzer P, Hambleton IR, Houehanou C, Howitt C, J Rgensen J, González-Rivas JP, Labadarios D, Marcus M, Martins J, Mwalim O, Nieto-Martínez R, Odili AN, Orazumbekova B, Perman G, Quesnel-Crooks S, Moghaddam SS, Sewpal R, Sousa-Uva M, Sulola MA, Venkataraman K, Vollmer S, Xueling S, Atun R, Banegas JR, Franco JVA, Arnott C, Chandiwana N, Huffman MD, Davies J, Ali MK, Flood D, Manne-Goehler J.
Lancet Diabetes Endocrinol
http://www.ncbi.nlm.nih.gov/pubmed/41519598